Effect of adjunctive inhalation on the association between plasma AUC/MIC of polymyxin B and clinical efficacy in MDR gram-negative infections
Journal of Antimicrobial Chemotherapy · 02.07.2026 · 81 (8)
DOI: 10.1093/jac/dkag238 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.07.2026. Verfasst von Shengnan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections, Plasma. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Changsha Natural Science Foundation, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Objectives
To develop a population pharmacokinetic (PPK) model of polymyxin B for intravenous (IV) and combined intravenous plus inhaled (IV + IH) administration in critically ill patients, and evaluate the association between plasma 24-h steady-state area under concentration–time curve to minimum inhibitory concentration ratio (AUCss,24h/MIC) and clinical outcomes.
Methods
In this prospective observational cohort study, adults with multidrug-resistant Gram-negative bacterial infections receiving polymyxin B ≥ 48 h were enrolled and assigned to IV or IV + IH groups. Plasma samples were analysed by validated HPLC–MS/MS. PPK models were developed with NONMEM. Clinical efficacy at the end of treatment was blindly assessed.
Results
Forty-three patients were enrolled (IV, n = 22; IV + IH, n = 21), with an overall clinical success rate of 66.7%. A two-compartment PPK model best described the data. The typical clearance was 2.61 L/h, with creatinine clearance and total bile acids identified as significant covariates. In the overall cohort, no significant differences in AUCss,24h or AUCss,24h/MIC were observed between clinical success and failure (P = 0.591 and 0.143, respectively). In the IV group, AUCss,24h/MIC was significantly higher in responders (P = 0.005), and an ROC analysis suggested an exploratory efficacy threshold of 94.4; AUCss,24h showed a non-significant trend (P = 0.076). No exposure–response relationship was observed in the IV + IH group (P = 0.398 and 0.495, respectively).
Conclusions
Plasma AUCss,24h/MIC appears to be associated with clinical efficacy during IV monotherapy but not in IV + IH regimens, possibly due to high pulmonary exposure. Plasma-based PK/PD targets should be applied cautiously when inhalation is added.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China.
- Center of Clinical Pharmacology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China.
- Department of Intensive Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China.
ORCID-Profile: Qi Pei
Förderung
- National Natural Science Foundation of China
- Changsha Natural Science Foundation
- Natural Science Foundation of Hunan Province
Zitieren
APA
Zhang, S., Li, Y., Tan, H., Li, Y., Qin, Y., Wu, T., Liu, J., & Pei, Q. (2026). Effect of adjunctive inhalation on the association between plasma AUC/MIC of polymyxin B and clinical efficacy in MDR gram-negative infections. Journal of Antimicrobial Chemotherapy, 81(8). https://doi.org/10.1093/jac/dkag238
Vancouver
Zhang S, Li Y, Tan H, Li Y, Qin Y, Wu T, et al. Effect of adjunctive inhalation on the association between plasma AUC/MIC of polymyxin B and clinical efficacy in MDR gram-negative infections. Journal of Antimicrobial Chemotherapy. 2026;81(8). doi:10.1093/jac/dkag238
BibTeX
@article{Zhang2026,
author = {Zhang, Shengnan and Li, Yaqian and Tan, Hongyi and Li, Yejun and Qin, Yuanfang and Wu, Tingting and Liu, Jingjing and Pei, Qi},
title = {Effect of adjunctive inhalation on the association between plasma AUC/MIC of polymyxin B and clinical efficacy in MDR gram-negative infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {8},
doi = {10.1093/jac/dkag238}
}
EUVIMED